Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 8/20 | 0.80 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 2/20 | 0.77 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 6/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.71 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | THRB | P10828 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289500 | 0.89 | RXFP1 (1.00) | FLT3RXFP1MEN1KMT2ATP53 | |
| SCHEMBL8288681 | 0.88 | RXFP1 (0.98) | FLT3RXFP1MEN1KMT2ATP53 | |
| SCHEMBL8289432 | 0.87 | KMT2A (1.00) | FLT3RXFP1MEN1KMT2AL3MBTL1 | |
| SCHEMBL5453222 | 0.86 | FLT3 (1.00) | FLT3RXFP1MEN1KMT2ATP53 | |
| SCHEMBL8290936 | 0.86 | FLT3 (0.82) | FLT3RXFP1MEN1KMT2ATP53 | |
| SCHEMBL8290774 | 0.86 | KMT2A (0.98) | FLT3RXFP1MEN1KMT2AMAPT | |
| SCHEMBL8288670 | 0.85 | FLT3 (0.80) | FLT3RXFP1MEN1KMT2ATP53 | |
| SCHEMBL5458963 | 0.85 | FLT3 (0.71) | FLT3RXFP1MEN1KMT2AMAPT | |
| SCHEMBL8289502 | 0.85 | KMT2A (0.75) | FLT3RXFP1MEN1KMT2ATP53 | |
| SCHEMBL8288812 | 0.84 | FLT3 (0.79) | FLT3RXFP1MEN1KMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | FLT3 3509/4885RXFP1 4595/4885MEN1 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.